LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

LLY

1,109.44

+0.48%↑

JNJ

239.41

+3.6%↑

ABBV

234.8

+2.18%↑

UNH

409.32

+0.85%↑

MRK

119.62

+3.62%↑

Search

Glaukos Corp

Chiusa

SettoreSettore sanitario

134.51 3.14

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

131.44

Massimo

135.19

Metriche Chiave

By Trading Economics

Entrata

114M

-20M

Vendite

7.5M

151M

EPS

-0.18

Margine di Profitto

-13.139

Dipendenti

1,094

EBITDA

124M

-5.3M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+17.59% upside

Dividendi

By Acuity

Utili prossimi

29 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

719M

7.9B

Apertura precedente

131.37

Chiusura precedente

134.51

Notizie sul Sentiment di mercato

By Acuity

50%

50%

143 / 342 Classifica in Healthcare

Glaukos Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Chi Siamo Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat